Roche to Buy PathAI for Up to $1.05 Billion to Bolster AI Diagnostics Tools
By Adria Calatayud
Roche Holding said it agreed to buy PathAI for up to $1.05 billion in a deal that seeks to bolster the artificial-intelligence offerings of its diagnostics division.
The Swiss pharmaceutical group said Thursday that the acquisition of U.S.-based PathAI would build on a partnership between the two companies formed in 2021 and take in-house an AI platform that aims to facilitate diagnostic workflows and help accelerate clinical-therapy development.
Under the deal, Roche agreed to pay $750 million upfront, with up to $300 million in additional payments subject to targets, it said. The deal is expected to close in the second half of the year.
Roche said that it intends to scale globally PathAI's technology for pathology laboratories and the biopharma industry. The company expects to combine PathAI's offerings with its own in order to drive laboratory efficiency and foster the discovery of potential drug targets and new diagnostic tools.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
May 07, 2026 02:06 ET (06:06 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for November
3 of the Best Dividend Stocks to Own
The 10 Best Companies to Invest in Now
It’s Been a Long Time Since Bonds Looked This Good
United States